Navigation Links
VIVUS Reports First Quarter 2011 Financial Results
Date:5/2/2011

MOUNTAIN VIEW, Calif., May 2, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its financial results for the first quarter ended March 31, 2011.

First Quarter ResultsFor the quarter ended March 31, 2011, VIVUS reported a net loss of $9.9 million or $0.12 per share as compared to a net loss of $18.8 million or $0.23 per share for the first quarter of 2010. The net loss from continuing operations was $9.9 million, or $0.12 net loss per share, as compared to a net loss from continuing operations of $16.6 million, or $0.21 net loss per share, during the first quarter of 2010. The lower net loss in 2011 as compared to 2010 results from reduced research and development spending on QNEXA® and avanafil as these projects progress from the clinical trial stage to the approval stage. The net loss for the first quarter last year also included a $2.2 million loss from discontinued operations of the MUSE business that was subsequently sold in the fourth quarter of 2010.  

Cash, Cash Equivalents and Available-for-Sale SecuritiesVIVUS had cash, cash equivalents and available-for-sale securities of $130.4 million at March 31, 2011, as compared to $139.2 million at December 31, 2010. The decrease in cash, cash equivalents and available-for-sale securities of $8.8 million is primarily due to cash used in operations and other net cash uses offset by proceeds of $1.5 million from the exercise of common stock options.

QNEXA Regulatory Update  VIVUS met with the Food and Drug Administration, or FDA, on April 14, 2011 to discuss the feasibility of performing a retrospective observational study utilizing existing electronic healthcare databases to assess fetal outcomes, which include major congenital malformations and oral cleft,
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. VIVUS to Present at Four Upcoming Investor Conferences in May
2. VIVUS to Present at the 10th Annual Needham Healthcare Conference
3. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
4. VIVUS to Present at Four Upcoming Investor Conferences
5. VIVUS to Present at Two Upcoming Investor Conferences
6. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
7. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
8. VIVUS to Present at Four Upcoming Healthcare Conferences
9. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
10. VIVUS to Present at the Needham and Company Life Sciences Conference
11. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Pittsburgh, PA (PRWEB) January 15, 2014 The ... Company, publisher of Food Safety Tech , an e-Journal ... has signed an agreement for the second year for the ... with Pittcon 2014. The partnership provides that the registration fee ...
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... Reston, VA (PRWEB) January 15, 2014 ... education have continued their sponsorship of an annual competition ... interest in, and access to, innovative STEM study. The ... , TEAMS: Tests of Engineering Aptitude, Mathematics, and ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... Blue Steel-Al Manhal Consortium, he stated that the agreement made would ... countries, cities, and governmental entities to solve the environmental ... ... (PRWEB) July 30, 2008 -- Spectrum Blue Steel Corporation announced today ...
... designed to accelerate recovery from central nervous system disorders, announced ... rehabilitative healthcare services, will expand the availability of the NESS ... System to 88 rehabilitation hospitals nationwide. , ... ...
... Development Of Lead Drug Candidates, MARKHAM, ON, ... of a CDN $45 million Series C financing. ... Tanabe Pharma Corporation ("MTPC"), and supported,by a number ... Inc., Caisse de Depot et Placement du Quebec, ...
Cached Biology Technology:Geecf: Spectrum Blue Steel Announces Strategic Partnership with Al Manhal International Group of Abu Dhabi to Deploy Biosphere Facilities 2 Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide 2 Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide 3Cytochroma Closes $45 Million Series C Financing 2Cytochroma Closes $45 Million Series C Financing 3
(Date:4/23/2014)... away from using triclosan as an antimicrobial ingredient in ... now scientists are reporting new evidence that appears to ... journal Chemical Research in Toxicology , found that ... promoted the growth of human breast cancer cells in ... Kyung-Chul Choi and colleagues note that hormonal imbalances seem ...
(Date:4/23/2014)... EMBO today announced Sophie Martin of the University ... EMBO Gold Medal. The award acknowledges her work to ... development of the cell. , Martin has been working ... in particular the way in which the spatial organization ... In the last 11 years, she has been using ...
(Date:4/23/2014)... disease is the first cause of dementia and affects ... cure has yet been found. One of the reasons ... cellular mechanisms which cause alterations in nerve transmissions and ... the disease., Researchers from the Institute of Neuroscience at ... mechanism involved in memory consolidation and were able to ...
Breaking Biology News(10 mins):In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2EMBO Gold Medal 2014 awarded to Sophie Martin 2Loss of memory in Alzheimer's mice models reversed through gene therapy 2
... Jerusalem, January 11, 2010 Why do some people ... the other hand, taking the opposite tack by buying insurance ... from the Hebrew University of Jerusalem and two Asian universities ... The team set out to tackle the long-standing question ...
... an enzyme in the brain with a specific kind of ... stroke, new research suggests. In a study using mouse ... E, an alternative to the popular drugstore supplement, stopped the ... The Ohio State University researchers have been studying how this ...
... unknown species of spider has been discovered in the dune ... by a team of scientists from the Department of Biology ... endangered. "The discovery of this new spider illustrates our obligation ... team of scientists. The Sands of Samar are the ...
Cached Biology News:Why do people 'play the longshot' and buy insurance? It's in our genes 2Study reveals how one form of natural vitamin E protects brain after stroke 2Study reveals how one form of natural vitamin E protects brain after stroke 3New spider species discovered by University of Haifa scientists 2
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation of endotoxins for research purposes. sensitivity 0.05-0.1 EU/mL...
... The Label IT siRNA Tracker Intracellular Localization ... directly label and deliver siRNA, of your ... for in vitro tracking experiments. Subcellular localization ... can be monitored following introduction of the ...
... MW: 60kDa (A) and 36kDa (C) ... pH 7.5, 500mM NaCl, 60mM 2-mercaptoethanol, ... 1mM DTT, and 0.1mg/ml serum albumin ... of proteins. Purification: DEAE chromatography, aminohexyl-agarose ...
... The Label IT siRNA Tracker Intracellular ... to directly label and deliver siRNA, of ... manner, for in vitro tracking experiments. Subcellular ... expression can be monitored following introduction of ...
Biology Products: